<DOC>
	<DOCNO>NCT00746746</DOCNO>
	<brief_summary>The purpose study determine safety give subject advance , recurrent refractory melanoma HyperAcute® Melanoma vaccine variant drug , call Interferon ( PEG-Intron® ) specially formulate give weekly basis ( instead daily ) . The study vaccine ( HyperAcute®-Melanoma ) make three type human melanoma cell line ( grown laboratory ) gene slightly change . This clinical study try discover safety study vaccine combine PEG-Intron® , side effect potential benefit , .</brief_summary>
	<brief_title>A Phase II Study Anti-Tumor Immunotherapy Regimen Comprised Pegylated Interferon-Alpha 2b HyperAcute Melanoma Vaccine Subjects With Advanced Melanoma</brief_title>
	<detailed_description>This study look anti-tumor vaccine effect , side effect toxicity HyperAcute® Vaccine PEG-Intron® . It hop immune system 's response genetically engineer melanoma cell PEG-Intron® cause reaction make react attack kill melanoma cell keep grow , possibly cause tumor shrink . Patients eligible 19 year old diagnose advanced , treatment resistant recurrent melanoma , aggressive usually pigment form skin cancer .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>19 year old Histological diagnosis melanoma AJCC Stage IIIC ( T , N1b , N2b , N3 , M0 ) Stage IV ( T , N , M1 ) , metastatic , progressive , refractory , recurrent high risk recurrence melanoma . Expected survival 6 month Adequate organ function Measurable nonmeasurable disease Must negative serology Hepatitis B C HIV prior enter study Must 4 week since major surgery , radiotherapy , chemotherapy biotherapy/targeted therapy Male female subject child produce potential must agree use contraception avoidance pregnancy measure enrol study one month last immunization . Active CNS metastases carcinomatous meningitis Hypercalcemia Pregnant nursing woman Other malignancy within five year History organ transplant current active immunosuppressive therapy Subjects take systemic corticosteroid therapy Active infection antibiotic within 1week prior study Uncontrolled significant congestive heart failure , myocardial infarction , ventricular arrhythmia pulmonary dysfunction Autoimmune disease A know allergy component HyperAcute vaccine PEGIntron Patients undergone splenectomy Patients sicklecell anemia thalassemia major .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Advanced Melanoma</keyword>
</DOC>